Search - tctmd.com

Displaying 221 - 240 of 348

Sort: Relevancy | Date

More Support for TMVR After Failed Mitral Bioprostheses

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

November 08, 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

News Conference News PCR London Valves 2017

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

September 28, 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

September 27, 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

September 24, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

August 27, 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

June 12, 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

May 18, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

May 16, 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

March 24, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.